First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Following the successful completion of the 7day BVLOS trials, Skye Air targets to undertake approximately 80 flights, each carrying blood samples and medicines for Aster Clinics
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
It is developing the drug candidate to potentially treat immunological diseases
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
Subscribe To Our Newsletter & Stay Updated
